louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04803318: Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Official title: Trametinib Combined With Everolimus and Lenvatinib in the Treatment of Recurrent/Refractory Advanced Solid Tumors: a Phase II Clinical Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Solid Tumor, Adult
Hepatocellular Carcinoma
Keywords: Hepatocellular Carcinoma;Lung Cancer
Trametinib
Everolimus
Lenvatinib
Lead sponsor: Second Affiliated Hospital of Guangzhou Medical University
Sponsor class: OTHER
First posted: 2021-03-17
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: To treat recurrent or refractory advanced solid tumors with multiple targeting drugs that inhibit several critical signaling pathways in cancer cells.
Primary purpose: TREATMENT

Brief summary: To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

Detailed description: The tumor diameter was measured and the efficacy was evaluated after treatment with Trametinib combined with Everolimus and Lenvatinib.

Eligibility criteria: Inclusion Criteria:

* Recurrent/Refractory advanced solid tumors
* Age between 18 and 85 years
* Expected life expectancy is greater than three months

Exclusion Criteria:

* Benign tumor
* Life expectancy is less than three months
* Serious medical commodities
* others

Primary outcomes:
measure: Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment.
timeFrame: up to 36 months
Secondary outcomes:
measure: Assessing progress free survival
timeFrame: 48 months
measure: Assessing overall survival
timeFrame: 48 months
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: The Second Affiliated Hospital of Guangzhou Medical University
state: Guangdong
Study officials:
affiliation: Second Affiliated Hospital of Guangzhou Medical University
name: Zhenfeng Zhang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01535118: A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)
Official title: National Allergies, Immunotherapy and RhinoConjunctivitis Survey in America
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Allergic Rhinoconjunctivitis
Keywords: Allergies
Immunotherapy
Lead sponsor: ALK-Abelló A/S
Sponsor class: INDUSTRY
First posted: 2012-02-17
Enrollment: 2765
Sex: ALL
Minimum age (years): 5
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults and children with ARC in the United States.

Brief summary: This study will gather information on allergic rhinoconjunctivitis from surveys completed by adults and children.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with hay fever, rhinitis or nasal and/or eye allergies and display symptoms of sneezing, itching, watery eyes, nasal congestion, or other nasal or eye allergy symptoms over the past 12 months OR take any medication for their hay fever, rhinitis, nasal or eye allergies
* 5 years of age or older
* Have a telephone

Exclusion Criteria:

* If less than 18 years old and there is no adult available that is knowledgeable about the participant's health

Primary outcomes:
measure: Percentage of Participants Who Experienced Daily Symptoms Due to Allergic Rhinoconjunctivitis (ARC)
timeFrame: Within 12 months prior to survey
measure: Percentage of Participants Who Experienced Work or School Absence Due to ARC in the Past 12 Months
timeFrame: Within 12 months prior to survey
measure: Percentage of Participants Who Used Medication to Treat ARC in the Past 12 Months
timeFrame: Within 12 months prior to survey
measure: Percentage of Participants Who Received Immunotherapy to Treat ARC
timeFrame: Within 12 months prior to survey
measure: Percentage of Participants Who Received Allergy Shots and Required Supplemental Prescription Allergy Medication
timeFrame: Within 12 months prior to survey
Secondary outcomes:
measure: Percentage of Participants Who Received Allergy Shots and Had a Co-morbid Condition of Asthma
timeFrame: Within 12 months prior to survey
Other outcomes:
Locations:
Study officials:
References:
citation: Blaiss MS, Dykewicz MS, Skoner DP, Smith N, Leatherman B, Craig TJ, Bielory L, Walstein N, Allen-Ramey F. Diagnosis and treatment of nasal and ocular allergies: the Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) surveys. Ann Allergy Asthma Immunol. 2014 Apr;112(4):322-8.e1. doi: 10.1016/j.anai.2014.02.006.
Clinical trial NCT02412618: Same-Day Mifepristone-Misoprostol Compared to Misoprostol Only for Surgical Abortion Cervical Preparation
Official title: A Randomized Comparison of Same-Day Oral Mifepristone-Misoprostol to Misoprostol Only for Cervical Preparation in Second Trimester Surgical Abortion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Induced Abortion
Lead sponsor: Medstar Health Research Institute
Sponsor class: OTHER
First posted: 2015-04-09
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A randomized double---blinded comparison of same---day mifepristone and misoprostol with misoprostol only for cervical preparation in second---trimester surgical abortion in 100 women at 14 0/7---19 6/7 weeks gestation.

Detailed description: Women desiring abortion at gestational ages between 14 weeks 0 days and 19 weeks 6 days were randomized to 200-mg mifepristone or identical placebo with 400-mcg misoprostol vaginally 4-6 hours prior to D\&E. Primary outcome was cervical dilation assessed by the largest Hegar dilator accepted without resistance. Secondary outcomes included total procedure time, and patient and provider perceptions. The study was powered to detect a 2-mm difference in cervical dilatation with 48 participants in each arm.

Eligibility criteria: Inclusion Criteria:

* healthy women
* eligible for non---urgent D\&E
* 14 0/7 weeks to 19 6/7 weeks gestation, confirmed by sonogram

Exclusion Criteria:

* emergent need for D\&E
* fetal demise
* intolerance
* allergy or contraindication to mifepristone or misoprostol

Primary outcomes:
measure: Initial Cervical Dilation
timeFrame: Assessed 4-6 hour following medications at time of D&E procedure
Secondary outcomes:
measure: Patient Acceptability and Assessment of Pain and Side Effects (5-point Likert Scale)
timeFrame: intraoperative
Other outcomes:
Locations:
Study officials:
References:
citation: Casey FE, Ye PP, Perritt JD, Moreno-Ruiz NL, Reeves MF. A randomized controlled trial evaluating same-day mifepristone and misoprostol compared to misoprostol alone for cervical preparation prior to second-trimester surgical abortion. Contraception. 2016 Aug;94(2):127-33. doi: 10.1016/j.contraception.2016.02.032. Epub 2016 Mar 4.
Clinical trial NCT03635918: Extensive Prospective Validation Study of the NightOwl Home Sleep Apnea Test
Official title: Extensive Prospective Validation Study of the NightOwl Home Sleep Apnea Test
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sleep Apnea
Lead sponsor: Ectosense NV
Sponsor class: INDUSTRY
Collaborators: name: Ziekenhuis Oost-Limburg
First posted: 2018-08-17
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Extensive Prospective validation study of the NightOwl, a Type IV home sleep apnea test (HSAT), compared to traditional PSG and HSAT monitors.

Detailed description: The purpose of this prospective validation study is the evaluation of the accuracy of the NightOwl HSAT to derive parameters relevant for the diagnosis of sleep apnea. The NightOwl HSAT comprises a finger or forehead mounted sensor and an automated analytics software. The sensor measures double-wavelength photo-plethysmography and accelerometry. The analytics software automatically interprets the sensor data and derives a measure of sympathetic activation of the autonomic nervous system, oxygen saturation, instantaneous pulse rate and activity. For each patient in the cohort, the AHI derived by the NightOwl will be compared to that of the Type I sleep monitor (in-lab PSG), which will acquire data simultaneously during the diagnostic night of the patient referred to the sleep lab for a polysomnography. On a randomly selected subset of patients, a benchmark HSAT will additionally be applied for comparison of its automated AHI derivation to that of the NightOwl.

Eligibility criteria: Inclusion Criteria:

* indication for a sleep study

Exclusion Criteria:

* Mentally disabled people

Primary outcomes:
measure: Apnea-Hypopnea Index (AHI)
timeFrame: For each included patient, the outcome measure will be assessed immediately after analysis of that patient's data by the NightOwl HSAT software
Secondary outcomes:
measure: Sleep-wake discrimination
timeFrame: For each included patient, the outcome measure will be assessed immediately after analysis of that patient's data by the NightOwl HSAT software
Other outcomes:
Locations:
city: Genk
country: Belgium
facility: Ziekenhuis Oost-Limburg
state: Limburg
Study officials:
affiliation: Ectosense NV
name: Frederik Massie, ir.
role: STUDY_DIRECTOR
References:
Clinical trial NCT01305018: Branched-chain Amino Acids Supplementation and Resistance Exercise-induced Muscle Damage and Inflammation
Official title: Effects of Leucine and Branched-chain Amino Acids (BCAA) Supplementation on Resistance Exercise-induced Muscle Damage and Inflammation: a Randomized, Double-blind, and Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: NA
Conditions: Muscle Damage
Inflammation
Keywords: Branched-chain amino acids
Leucine
Muscle damage
Inflammation
supplementation
resistance exercise-induced
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2011-02-28
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate the effects of branched-chain amino acids (BCAA) supplementation on resistance exercise-induced muscle damage and inflammation.


Eligibility criteria: Inclusion Criteria:

* Sedentary;
* No muscle disorders;
* Must be able to swallow tablets

Primary outcomes:
measure: Muscle maximal strength
timeFrame: 4 days
measure: Muscle edema
timeFrame: 4 days
measure: Muscle soreness
timeFrame: 4 days
Secondary outcomes:
measure: Muscle inflammation
timeFrame: 4 days
measure: Muscle damage
timeFrame: 4 days
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: University of São Paulo - School of Physical Education and Sports
Study officials:
References:
Clinical trial NCT03520218: Evaluating Positron Emission Mammography Imaging of Suspicious Breast Abnormalities
Official title: A Pilot Study to Evaluate Low-Dose Positron Emission Mammography Imaging in Visualization and Characterization of Suspicious Breast Abnormalities
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2018-05-09
Enrollment: 25
Sex: FEMALE
Minimum age (years): 26
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The goal of this pilot project is to test the new Radialis Positron Emission Mammography (R-PEM) system in breast cancer patients that has a higher sensitivity with lower radiation doses than conventional PET/CT.

The plan for the pilot study is to image patients who are already scheduled for diagnostic imaging for breast cancer after a positive core biopsy. Participants will be injected with 5mCi (millicurie) of F18-Fluorodeoxyglucose (FDG) and patient will wait for a couple of hours for uptake of FDG. After this time, the first R-PEM scan will occur. Additional optional R-PEM scans can be performed 4 hours after injection and 7 hours after injection with reductions in radiation emission.

Additionally, R-PEM images will be compared to standard-of-care breast Magnetic Resonance Imaging (MRI) and digital breast tomosynthesis (DBT) to study extension of disease and screening of contralateral breast.


Eligibility criteria: Inclusion Criteria:

* Subject is female of any race and ethnicity
* Subject is at least 26 years old
* Following routine mammography imaging, subject is categorized as BI-RADS score 4C or 5 because of calcifications, masses, asymmetries or/and architectural distortion will undergo additional tests including biopsy within 30 days of routine imaging
* Subject is female with a recent breast biopsy confirming breast cancer

Exclusion Criteria:

* Subject unable or unwilling to undergo informed consent
* Subjects who are unable or unwilling to tolerate any of the imaging tests because of claustrophobia, compression, etc.
* Subjects who are pregnant or who think they may be pregnant
* Subjects who are breast-feeding
* Subjects weight exceed table limits of MRI and PET-CT (300-450 lb or 135-205 kg)
* Subjects with history of allergic reaction to gadolinium or previous history of life-threatening anaphylactic reaction to any contrast.
* Claustrophobic subjects

Primary outcomes:
measure: Evaluating Performance of the R-PEM system as the Dose Decays
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre, University Health Network, 610 University Ave.
state: Ontario
Study officials:
affiliation: University Health Network, Toronto
name: Vivianne Freitas, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02618018: Clinical Evaluation of Efficacy and Stability of AT TORBI 709M 4-haptic Toric IOL in Cataract Surgery
Official title: An Investigator-Initiated Trials on the Efficacy and Stability of AT TORBI 709M 4-haptic Toric IOL in Cataract Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Iol
Astigmatism
Keywords: astigmatism
toric intraocular lens
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2015-12-01
Enrollment: 20
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and stability of AT TORBI 709M 4-haptic toric IOL in cataract surgery.

Detailed description: Inclusion criteria

1. senile cataract
2. patients' age of 21 years or older
3. preoperative regular corneal astigmatism between 1.00 D and 6.00 D

Exclusion criteria

1. pregnant, lactating women
2. presence of other ocular diseases which affect stability of lens capsule

Primary outcome : efficacy index (visual acuity, refractive results Secondary outcome : rotational stability, endothelial cell count, cornea thickness

Eligibility criteria: Inclusion Criteria:

* senile cataract
* patients' age of 21 years or older
* preoperative regular corneal astigmatism between 1.00 D and 6.00 D

Exclusion Criteria:

* pregnant, lactating women
* presence of other ocular diseases which affect stability of lens capsule

Primary outcomes:
measure: Visual acuity, refractive results
timeFrame: 3 months
Secondary outcomes:
measure: Rotational stability
timeFrame: 3 months
measure: Endothelial cell count
timeFrame: 3 months
measure: Cornea thickness
timeFrame: 3 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Mee Kum Kim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01470118: A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Conjunctivitis, Allergic
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2011-11-11
Enrollment: 127
Sex: ALL
Minimum age (years): 10
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.


Eligibility criteria: Inclusion Criteria:

* History of eye allergies within the past 24 months
* Willing to not wear contact lenses at least 72 hours prior to the study start and during the study period

Exclusion Criteria:

* Current eye infection
* Eye surgery within 3 months or vision correction surgery within 6 months
* Any planned surgery during the study or 30 days after the study

Primary outcomes:
measure: Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 0 at Hour 16
timeFrame: Day 0 Hour 16
measure: Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 14 at Hour 24
timeFrame: Day 14 Hour 24
Secondary outcomes:
measure: Conjunctival Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24
timeFrame: Day 14 Hour 24
measure: Ciliary Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24
timeFrame: Day 14 Hour 24
measure: Episcleral Redness Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24
timeFrame: Day 14 Hour 24
measure: Chemosis Evaluated by the Investigator at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24
timeFrame: Day 14 Hour 24
measure: Eyelid Swelling Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24
timeFrame: Day 14 Hour 24
measure: Tearing Evaluated by the Subject at 7, 15, and 20 Minutes Post Challenge on Day 14 at Hour 24
timeFrame: Day 14 Hour 24
Other outcomes:
Locations:
city: Philadelphia
country: United States
state: Pennsylvania
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
citation: McLaurin EB, Marsico NP, Ackerman SL, Ciolino JB, Williams JM, Villanueva L, Hollander DA. Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials. Adv Ther. 2014 Oct;31(10):1059-71. doi: 10.1007/s12325-014-0155-3. Epub 2014 Sep 27.
Clinical trial NCT01680913: Does Ultrasound Guidance Improve Time to Perform a Spinal or Number of Attempts in Obese Patients?
Official title: Does Ultrasound Guidance Improve Time to Perform a Spinal or Number of Attempts in Obese Patients? A Randomized Controlled Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Spinal Anesthesia Administration
Lead sponsor: University of Saskatchewan
Sponsor class: OTHER
First posted: 2012-09-07
Enrollment: 67
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Spinal anesthesia depends on being able to locate physical landmarks on a patient's body. In obese patients, the commonly used landmarks may be difficult or even impossible to feel. In addition, the spine can be hidden beneath a layer of fatty tissue.

Ultrasound is useful for finding the correct injection site in pregnant patients, but the usefulness of ultrasound has not been adequately evaluated in non-pregnant patients. The potential benefits for obese patients from the use of ultrasound include shortening the duration of the procedure, increasing patient comfort, decreasing the total number of attempts, and aiding in the choice of appropriate needle length for the patient.

The investigators hypothesize that there is no difference in time to perform a spinal anesthetic when landmarking with ultrasound as compared to tactile landmarking in patients with BMI \> 35.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing surgeries amenable to spinal anesthetic
* BMI \>35
* between the ages of 18-85

Exclusion Criteria:

* Patients with known spinal disease or previous spinal surgery
* Pregnant patients
* Patients requiring emergent surgeries
* Patients in positions other than sitting during neuroaxial anesthesia
* Patients with contraindications to neuroaxial anesthesia

Primary outcomes:
measure: Total time to perform the spinal
timeFrame: From the beginning of palpation or ultrasound to free flow of Cerebral Spinal Fluid (CSF), up to 1 hour.
Secondary outcomes:
measure: Time from administration of the local anesthetic needle until free flow CSF
timeFrame: Up to 1 hour
measure: Number of needle redirections
timeFrame: At time of spinal anesthetic administration
measure: Number of attempts to complete the spinal
timeFrame: At time of spinal anesthetic administration
measure: Number of failed blocks
timeFrame: Up to 15 minutes after administration of spinal anesthesia
Other outcomes:
Locations:
city: Saskatoon
country: Canada
facility: Saskatoon City Hospital
state: Saskatchewan
city: Saskatoon
country: Canada
facility: Saint Paul's Hospital
state: Saskatchewan
Study officials:
affiliation: University of Saskatchewan
name: Jacelyn Larson, MD FRCP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00162513: Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia
Official title: Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: Chronic Myeloid Leukemia
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2005-09-13
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Donors with CM will be solicited from a waiting list of patients awaiting BMT from the waiting list of MUD searches.

Maximally matched donor will be searched for each eligible CML patient with a goal in mind to find other patients with CML that share both class I and class II determinants. Sharing of one class I II will be considered eligible for participation in the study. Peripheral blood and PBMC from the donors will be isolated, washed and irradiated.

The cells will be injected into the consenting patients intracutaneously at 2 weeks intervals for a total of 6 injections.


Eligibility criteria: Inclusion Criteria:

* Patients above the age of 55 consenting to participate in the study.
* Patients with documented CML with Philadelphia chromosome t (9:21)
* Patients with no HLA matched sibling.
* Patients eligible for BMT for who no matched unrelated donor can be identified after completion of an international donor search lasting for more than six months, or patients that have failed BMT.
* Patients with contra-indication to BMT.
* Patients refusing BMT.
* Patients who failed interferon alpha, ARAc and/or Glivec.

Exclusion Criteria:

* Patients requiring immunosuppressive therapy or corticosteroids.

Primary outcomes:
measure: Investigate the feasibility of allogeneic tumor cell vaccine for patients with resistant CML.
Secondary outcomes:
measure: To induce immunity against a putative bcr/abl peptide bound to MHC identical class I, II or preferably both.
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
Study officials:
affiliation: Hadassah Medical Organization
name: Shimon Slavin, MD
role: PRINCIPAL_INVESTIGATOR
References: